On the role of the immunoproteasome in transplant rejection.


Journal

Immunogenetics
ISSN: 1432-1211
Titre abrégé: Immunogenetics
Pays: United States
ID NLM: 0420404

Informations de publication

Date de publication:
03 2019
Historique:
received: 17 07 2018
accepted: 04 09 2018
pubmed: 17 9 2018
medline: 10 8 2019
entrez: 17 9 2018
Statut: ppublish

Résumé

The immunoproteasome is expressed in cells of hematopoietic origin and is induced during inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been shown to be therapeutically effective in pre-clinical models for autoimmune diseases, colitis-associated cancer formation, and transplantation. Immunoproteasome inhibition prevents activation and proliferation of lymphocytes, lowers MHC class I cell surface expression, reduces the expression of cytokines of activated immune cells, and curtails  T helper 1 and 17 cell differentiation. This might explain the in vivo efficacy of immunoproteasome inhibition in different pre-clinical disease models for autoimmunity, cancer, and transplantation. In this review, we summarize the effect of immunoproteasome inhibition in different animal models for transplantation.

Identifiants

pubmed: 30220008
doi: 10.1007/s00251-018-1084-0
pii: 10.1007/s00251-018-1084-0
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Proteasome Inhibitors 0
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

263-271

Références

EMBO Mol Med. 2014 Feb;6(2):226-38
pubmed: 24399752
Ann Rheum Dis. 2015 Jul;74(7):1474-8
pubmed: 25710470
Biol Blood Marrow Transplant. 2015 Sep;21(9):1555-64
pubmed: 26093043
Int Immunopharmacol. 2017 Sep;50:48-54
pubmed: 28628770
Transplantation. 2009 May 27;87(10):1555-61
pubmed: 19461494
Kidney Int. 2018 Mar;93(3):670-680
pubmed: 29229189
PLoS Pathog. 2016 Apr 29;12(4):e1005593
pubmed: 27128676
Circulation. 2011 Sep 13;124(11 Suppl):S187-96
pubmed: 21911812
Science. 1994 Aug 26;265(5176):1234-7
pubmed: 8066463
PLoS One. 2011 Feb 03;6(2):e14646
pubmed: 21304910
Clin Exp Immunol. 2012 Jun;168(3):268-73
pubmed: 22519588
Mol Ther. 2016 Nov;24(11):1898-1912
pubmed: 27506451
Int J Hematol. 2012 Dec;96(6):764-72
pubmed: 23179902
Curr Opin Immunol. 2004 Oct;16(5):550-7
pubmed: 15341998
Biol Blood Marrow Transplant. 2015 Nov;21(11):1907-13
pubmed: 26055298
Transplantation. 2010 Feb 15;89(3):277-84
pubmed: 20145517
Biol Blood Marrow Transplant. 2017 Oct;23(10):1651-1657
pubmed: 28549771
Pediatr Nephrol. 2016 Aug;31(8):1341-8
pubmed: 27048228
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8425-E8432
pubmed: 27956634
Eur J Immunol. 2014 Dec;44(12):3508-21
pubmed: 25231383
J Immunol. 2009 Nov 15;183(10):6145-50
pubmed: 19841190
Arthritis Rheum. 2012 Feb;64(2):493-503
pubmed: 21905015
J Exp Med. 2001 Jun 4;193(11):1319-26
pubmed: 11390439
Arthritis Res Ther. 2017 Aug 11;19(1):187
pubmed: 28800777
Nat Med. 2008 Jul;14(7):748-55
pubmed: 18542049
J Immunol. 2004 Sep 15;173(6):3925-34
pubmed: 15356141
Eur J Immunol. 2016 Jan;46(1):104-13
pubmed: 26464284
Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5
pubmed: 15148407
Am J Pathol. 2010 Sep;177(3):1265-73
pubmed: 20651239
Cell. 1994 Sep 9;78(5):761-71
pubmed: 8087844
Brain Behav Immun. 2018 Oct;73:167-179
pubmed: 29679638
Cell Death Differ. 2016 Jun;23(6):1026-37
pubmed: 26990663
Nephrol Dial Transplant. 2010 Nov;25(11):3764-73
pubmed: 20466656
Cell Mol Immunol. 2017 Jul 10;:
pubmed: 28690324
J Biol Chem. 2001 Sep 28;276(39):36474-81
pubmed: 11479311
J Exp Med. 2001 Jul 2;194(1):1-12
pubmed: 11435468
J Clin Oncol. 2012 Sep 10;30(26):3202-8
pubmed: 22869883
Curr Opin Immunol. 2013 Feb;25(1):74-80
pubmed: 23219269
J Immunol. 2011 Dec 1;187(11):5548-57
pubmed: 22013127
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5042-7
pubmed: 16549793
Mol Immunol. 2017 Aug;88:32-37
pubmed: 28582644
J Immunol. 2010 Jul 1;185(1):634-41
pubmed: 20525886
Cell. 2012 Feb 17;148(4):727-38
pubmed: 22341445
Microbes Infect. 2008 Mar;10(3):241-50
pubmed: 18321749
Nat Rev Immunol. 2010 Jan;10(1):73-8
pubmed: 20010787
Cancer Res. 1999 Jun 1;59(11):2615-22
pubmed: 10363983
Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8
pubmed: 9871680
Oncotarget. 2017 Feb 7;8(31):50873-50888
pubmed: 28881611
Bone Marrow Transplant. 2009 Feb;43(3):253-9
pubmed: 18806836
Immunity. 1994 Oct;1(7):533-41
pubmed: 7600282
J Immunol. 2012 Oct 15;189(8):4182-93
pubmed: 22984077
Immunology. 2008 Jun;124(2):234-46
pubmed: 18217957
Eur J Immunol. 2018 Mar;48(3):419-429
pubmed: 29067678
Clin Exp Immunol. 2018 Aug;193(2):194-206
pubmed: 29603201
Oncotarget. 2017 Jan 10;8(31):50447-50459
pubmed: 28881574
Biol Blood Marrow Transplant. 2015 Jul;21(7):1315-20
pubmed: 25765556
Blood. 2006 May 1;107(9):3575-83
pubmed: 16282346
J Immunol. 2006 Jun 1;176(11):6665-72
pubmed: 16709825
Nat Immunol. 2011 Dec 25;13(2):129-35
pubmed: 22197977
J Immunol. 2010 Nov 1;185(9):5549-60
pubmed: 20881186
Int Urol Nephrol. 2016 Jun;48(6):907-15
pubmed: 26920131
Br J Pharmacol. 2018 Jan;175(1):38-52
pubmed: 29034459
Haematologica. 2018 Mar;103(3):522-530
pubmed: 29326124
J Neuroimmunol. 2017 Oct 15;311:71-78
pubmed: 28844501
Nat Immunol. 2016 Aug;17(8):938-45
pubmed: 27294792
Cold Spring Harb Perspect Med. 2013 Sep 01;3(9):a015487
pubmed: 24003247
EMBO Mol Med. 2018 Feb;10(2):200-218
pubmed: 29295868
Nat Commun. 2017 Nov 22;8(1):1692
pubmed: 29167449
Leukemia. 2007 Jul;21(7):1464-71
pubmed: 17495970
Pediatr Nephrol. 2010 Jan;25(1):61-74
pubmed: 21476231
FASEB J. 2017 Apr;31(4):1756-1766
pubmed: 28096232
Immunity. 1999 Oct;11(4):483-93
pubmed: 10549630
Transplantation. 2008 Dec 27;86(12):1754-61
pubmed: 19104417
Eur J Immunol. 2006 Mar;36(3):681-9
pubmed: 16479541
Sci Rep. 2018 Apr 13;8(1):5975
pubmed: 29654304
Nat Med. 2009 Jul;15(7):781-7
pubmed: 19525961
Infect Immun. 2018 Feb 20;86(3):
pubmed: 29263103
J Am Soc Nephrol. 2018 Feb;29(2):591-605
pubmed: 29242250
Sci Rep. 2016 Jan 18;6:19434
pubmed: 26776888

Auteurs

Michael Basler (M)

Division of Immunology, Department of Biology, University of Konstanz, P1101 Universitätsstrasse 10, D-78457, Konstanz, Germany. Michael.Basler@uni-konstanz.de.
Biotechnology Institute Thurgau (BITg), University of Konstanz, CH-8280, Kreuzlingen, Switzerland. Michael.Basler@uni-konstanz.de.

Jun Li (J)

Division of Immunology, Department of Biology, University of Konstanz, P1101 Universitätsstrasse 10, D-78457, Konstanz, Germany.
Department of Urology Oncological Surgery, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, 400030, China.

Marcus Groettrup (M)

Division of Immunology, Department of Biology, University of Konstanz, P1101 Universitätsstrasse 10, D-78457, Konstanz, Germany. Marcus.Groettrup@uni-konstanz.de.
Biotechnology Institute Thurgau (BITg), University of Konstanz, CH-8280, Kreuzlingen, Switzerland. Marcus.Groettrup@uni-konstanz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH